Michael Carrier's Avatar

Michael Carrier

@mcarrier.bsky.social

Professor at Rutgers Law School specializing in antitrust and IP law.

691 Followers  |  462 Following  |  2,460 Posts  |  Joined: 12.11.2024  |  1.5449

Latest posts by mcarrier.bsky.social on Bluesky

Rule or Reason? The Role of Balancing in Antitrust Law Antitrust law has two basic ways of analyzing conduct alleged to be anticompetitive. Some conduct is viewed as so inherently pernicious that it is deemedΒ i

In a piece just published in the Notre Dame Law Review, @marklemley.bsky.social & I argue that courts are confused about how to apply the rule of reason and explain the importance of a four-step test that includes balancing of costs and benefits. papers.ssrn.com/sol3/papers....

07.10.2025 20:08 β€” πŸ‘ 8    πŸ” 3    πŸ’¬ 0    πŸ“Œ 0
Of Labor, Antitrust, and Why the Proposed House Settlement Will Not Solve the NCAA's Problem The NCAA recently settled three antitrust lawsuits. With a significant payout, it hopes to put its antitrust worries behind it. In doing so, it seeks to follow

Honored to receive the β€œOutstanding Sports and Entertainment Law Paper” from the Academy of Legal Studies in Business for the paper Marc Edelman and I wrote: β€œOf Labor, Antitrust, and Why the Proposed House Settlement Will Not Solve the NCAA’s Problem.” papers.ssrn.com/sol3/papers....

26.08.2025 23:10 β€” πŸ‘ 5    πŸ” 1    πŸ’¬ 2    πŸ“Œ 1
Video thumbnail

▢️ #RutgersLaw Professor @mcarrier.bsky.social spoke in a recent Dept. of Justice/Federal Trade Commission listening session on "Lowering Americans Drug Prices Through Competition." In this video, he gives background on cases of 'product hopping.' : www.justice.gov/opa/video/do...
#lawsky

10.07.2025 16:18 β€” πŸ‘ 1    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0
Preview
The Innovation/Access Tradeoff, Part 1000 From the perspective of intellectual property (IP) and antitrust law, the overriding question in the pharmaceutical industry is how to navigate the tradeoff between innovation and access. It is into t...

Rutgers Law Professor @mcarrier.bsky.social comments on an article by William Feldman which discusses various anticompetitive behavior including "patent thickets" and "product hopping": pmc.ncbi.nlm.nih.gov/articles/PMC...
#lawsky

09.07.2025 17:48 β€” πŸ‘ 2    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0

Can we get a big Texas yeehaw?! The Lone Star State just signed the seventh state Right to Repair law for electronics. It’s also the first electronics repair law to pass in a state led by a Republican, but we’re only surprised it took this long.

24.06.2025 22:54 β€” πŸ‘ 12    πŸ” 3    πŸ’¬ 1    πŸ“Œ 0
Preview
Axios Event: "Broken" American health care system draws bipartisan focus, lawmakers say Improving drug access and affordability is a key health care policy issue with strong bipartisan support, health care experts said at an Axios roundtable on June 12.

For @axios.com health care roundtable, I discuss bipartisan legislation that would lower drug prices.
www.axios.com/2025/06/17/a...

17.06.2025 18:30 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 1    πŸ“Œ 1

And another..."Notice pleading requires fair notice to defendants. It can’t be reasonably argued that Deere is scratching its metaphorical head and muttering, 'I wonder what the Governments are complaining about?'”

11.06.2025 16:42 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

Court denies Deere's motion with colorful language. I've discussed concerns with abuse of consumers' right to repair...https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4200736

11.06.2025 16:42 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

And another..."Notice pleading requires fair notice to defendants. It can’t be reasonably argued that Deere is scratching its metaphorical head and muttering, 'I wonder what the Governments are complaining about?'”

11.06.2025 16:33 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

Court denies Deere's motion with colorful language. I've discussed concerns with the abuse of the "right to repair"...https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4200736

11.06.2025 16:33 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

#RutgersLaw Professor @mcarrier.bsky.social weighs in and says appeals and more lawsuits are expectedπŸ‘‡
#lawsky

11.06.2025 14:43 β€” πŸ‘ 0    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Of Labor, Antitrust, and Why the Proposed House Settlement Will Not Solve the NCAA's Problem The NCAA recently settled three antitrust lawsuits. With a significant payout, it hopes to put its antitrust worries behind it. In doing so, it seeks to follow

The NCAA settlement is big news but, as @profmarcedelman.bsky.social & I explain, doesn’t provide antitrust immunity. Why? Because unlike professional sports leagues, no union = no antitrust exemption.

09.06.2025 20:57 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Standards Organizations: The Missing Link in Fixing FRAND Evasion Standards, common platforms that allow products to work together, offer benefits to society. But standards typically involve patents. And the owner of a patent

Patentees can abuse standards to β€œhold up” an industry. And even if they promise to reasonably license their patents, these commitments have been evaded through β€œpatent pools.” David Katz and I discuss.

30.04.2025 17:27 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
The Missing Caselaw of Reverse-Payment Settlements In 2013, the Supreme Court issued one of the most important antitrust rulings in the past generation. In <i>FTC v. Actavis</i>, the Court held that agreements b

Why is the law unclear on agreements by which brand firms pay generics to delay entry? Some say because of a 2013 Supreme Court decision. Based on a comprehensive review of the caselaw, Ed Bank and I highlight another reason: the settlement of antitrust challenges to these agreements before verdict.

29.04.2025 16:03 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Of Labor, Antitrust, and Why the Proposed House Settlement Will Not Solve the NCAA's Problem The NCAA recently settled three antitrust lawsuits. With a significant payout, it hopes to put its antitrust worries behind it. In doing so, it seeks to follow

As the court decides whether to approve the college-athlete settlement in House v. NCAA, the settlement’s salary cap will not be immune from future antitrust lawsuits. Marc Edelman & I explain...

14.04.2025 15:38 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Avanci's Admissions Cast Doubt on Pool's Procompetitive Effects Patent pools have historically been viewed as procompetitive. And the latest pool receiving widespread attention, the Avanci pool, has gained support for this r

Collections of patents known as pools can offer benefits but also can harm competition. The Avanci pool covering the auto industry reflects the latter, with Brian Scarpelli, Priya Nair, and I explaining how the pool’s concessions in a UK hearing are at odds with what it has told the industry.

01.04.2025 02:27 β€” πŸ‘ 0    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Preview
Trump nominee unites right and left with tough antitrust view Oxford-educated Gail Slater’s concerns about market concentration have caused disquiet on Wall Street

β€œWe’re not likely to see the foot being let off the gas completely”.

- #RutgersLaw Professor @mcarrier.bsky.social weighing in on what may be a continuation of previous enforcement by the President's pick to lead the Justice Department’s antitrust division: www.ft.com/content/7697...
#lawsky

11.03.2025 14:03 β€” πŸ‘ 0    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0
PBMs: The Hidden Actor Behind Product Hopping <br> The issue of high U.S. prescription drug prices has received significant attention. In recent congressional hearings, brand-name drug companies have blamed phar

Drug firms engage in β€œproduct hopping” by switching from one version to a similar one. PBMs list drugs on their formularies based on rebates. Victoria Field & I show a new type of harm from the combination of these two activities.

06.03.2025 16:13 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

...Elizabeth Arthur, Doni Bloomfield, Gwendolyn J. Lindsay Cooley, Robin Feldman, Victoria Field, @marklemley.bsky.social, Arti Rai, @rachelsachs.bsky.social, @asarpatwari.bsky.social, and Sean Tu. Without harming innovation, there are many things we can do to lower high drug prices!

24.02.2025 23:39 β€” πŸ‘ 3    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

Thanks to my co-organizer and host Christopher Leslie for a great conference at UC Irvine School of Law bringing together scholars and enforcement officials to discuss pharmaceutical competition. And grateful for the fabulous contributions of...

24.02.2025 23:39 β€” πŸ‘ 8    πŸ” 2    πŸ’¬ 3    πŸ“Œ 0
Preview
Thomas Kauper Obituary (09/25/1935 - 02/09/2025) - Ann Arbor, MI - Ann Arbor News View Thomas E. Kauper's obituary, send flowers and sign the guestbook.

Sad to hear about the loss of Tom Kauper, head of the Antitrust Division in the β€˜70s (filing the case that led to the breakup of AT&T). His courses in antitrust changed my life and I’m glad I had the chance to share that with him.

13.02.2025 14:22 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
Judge weighs NCAA's $2.8B deal amid objections Over a dozen objections were filed against the nearly $2.8 billion NCAA antitrust settlement ahead of Friday's deadline. A hearing for the the settlement has been scheduled for April 7.

#RutgersLaw Prof. @mcarrier.bsky.social explains to ESPN why the $2.8B antitrust NCAA settlement is good for current student-athletes but might not be ideal for future student-athletes who challenge restraints:
www.espn.com/college-spor...

03.02.2025 17:39 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
An Antitrust Analysis of the NCAA Transfer Policy <div> The National Collegiate Athletic Association ("NCAA") is no stranger to antitrust law. As a trade association composed of nearly all U.S. colle

NCAA president Charlie Baker is talking about limiting the dates in which college athletes can declare to transfer to just a 10 day period. In the academic world, @mcarrier.bsky.social and I have published on the antitrust risks. Link below if anyone is interested: dx.doi.org/10.2139/ssrn...

15.01.2025 17:05 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 0    πŸ“Œ 1
How the Federal Trade Commission Can Use Section 5 To Strengthen the Right to Repair Consumers’ right to repair their products is under attack. Manufacturers have decimated this long-held right by making parts unavailable, preventing products fr

For a more comprehensive look at Deere’s anticompetitive actions and lack of justifications...

15.01.2025 19:50 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

Though the last-minute nature of the filing led to a 3-2 FTC vote, I explain how β€œright to repair” is not a partisan issue.

15.01.2025 19:50 β€” πŸ‘ 6    πŸ” 3    πŸ’¬ 0    πŸ“Œ 0
The Antitrust Case Against Live Nation Entertainment In November 2022, millions of Taylor Swift fans were angry. For the first time since 2018, Swift was going on tour. Demand was through the roof. But the process

Thanks to @blueark.app, I imported a decade of posts from Twitter. My #1 topic for 2024: why Live Nation/Ticketmaster is a walking antitrust violation (papers.ssrn.com/sol3/papers....) and why the DOJ/state lawsuit is so strong.

31.12.2024 20:32 β€” πŸ‘ 3    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

The Federal Circuit correctly upholds the district court decision requiring Teva to delist from the Orange Book patents that should never have been there; @mcarrier.bsky.social and I filed an amicus brief urging this result.

cafc.uscourts.gov/opinions-ord...

20.12.2024 16:46 β€” πŸ‘ 9    πŸ” 3    πŸ’¬ 1    πŸ“Œ 0
Preview
US healthcare deal advisers seek lighter supervision Experts expect Trump regulators to be less hawkish on challenging proposed acquisitions in the sector

I explain that new antitrust enforcers will continue to bring pharmaceutical cases, but following more traditional antitrust theories.

12.12.2024 19:54 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Pharmaceutical Antitrust Enforcement in the Biden Administration <br> <p></p> <p>Pharmaceutical antitrust enforcement in the Biden administration has pushed the boundaries. Previously focused on conduct such as β€œreverse payment” s

My latest piece explains how the Biden administration has enforced antitrust law in the pharmaceutical industry, discussing FDA patent listings, merger enforcement, and pharmacy benefit managers (PBMs).

25.11.2024 19:19 β€” πŸ‘ 12    πŸ” 3    πŸ’¬ 2    πŸ“Œ 0

This would be unfortunate. As I've explained, this is an easy case: large anticompetitive effects and limited benefits. papers.ssrn.com/sol3/papers....

13.11.2024 02:47 β€” πŸ‘ 3    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

@mcarrier is following 18 prominent accounts